Soleno Therapeutics (SLNO) News Today $74.23 +1.96 (+2.71%) Closing price 04/24/2025 04:00 PM EasternExtended Trading$73.50 -0.73 (-0.99%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Soleno Therapeutics price target raised to $145 from $93 at Piper SandlerApril 25 at 2:39 AM | markets.businessinsider.comPiper Sandler Sticks to Its Buy Rating for Soleno Therapeutics (SLNO)April 25 at 2:39 AM | markets.businessinsider.comAvoro Capital Advisors LLC Has $113.50 Million Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO)Avoro Capital Advisors LLC increased its stake in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 15.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,525,000 sharesApril 23 at 7:22 AM | marketbeat.comSoleno Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 7, 2025, at 4:30 PM ETApril 23 at 7:00 AM | globenewswire.com124,095 Shares in Soleno Therapeutics, Inc. (NASDAQ:SLNO) Bought by Rock Springs Capital Management LPRock Springs Capital Management LP acquired a new stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 124,095 shares of the company's stock,April 23 at 6:56 AM | marketbeat.comMarshall Wace LLP Grows Stock Holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO)Marshall Wace LLP increased its stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 61.3% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 399,849 shares of the company's stock after buying an additional 152,010April 23 at 4:42 AM | marketbeat.comNan Fung Group Holdings Ltd Boosts Stock Holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO)Nan Fung Group Holdings Ltd lifted its stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 24.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 79,650 shares of the company's stock after purchasApril 21, 2025 | marketbeat.comWalleye Capital LLC Invests $3.46 Million in Soleno Therapeutics, Inc. (NASDAQ:SLNO)Walleye Capital LLC purchased a new stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 76,934 shares of the company's stock, valued at approximately $3,458,00April 20, 2025 | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Acquired by Geode Capital Management LLCGeode Capital Management LLC increased its position in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 10.9% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 599,119 shares of the company'April 20, 2025 | marketbeat.comAltium Capital Management LLC Increases Holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO)Altium Capital Management LLC raised its stake in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 17.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 250,000 shares of the company's stock after acquiring an additional 3April 19, 2025 | marketbeat.comFranklin Resources Inc. Takes Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO)Franklin Resources Inc. bought a new stake in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 15,000 shares of the company's stock, valued at approximately $67April 19, 2025 | marketbeat.comHC Wainwright Reiterates Buy Rating for Soleno Therapeutics (NASDAQ:SLNO)HC Wainwright restated a "buy" rating and issued a $100.00 price objective on shares of Soleno Therapeutics in a report on Tuesday.April 17, 2025 | marketbeat.comCarlyle Group Inc. Decreases Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO)Carlyle Group Inc. decreased its stake in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 66.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,375,646 shares of theApril 16, 2025 | marketbeat.comSoleno Therapeutics announces VYKAT XR launchApril 15, 2025 | markets.businessinsider.comSoleno Launches Pill For Hyperphagia In Prader-Willi Syndrome Patients But Retail’s UnmovedApril 14, 2025 | msn.comSoleno Therapeutics Announces VYKAT(TM) XR LaunchApril 14, 2025 | globenewswire.com47,794 Shares in Soleno Therapeutics, Inc. (NASDAQ:SLNO) Purchased by F M Investments LLCF M Investments LLC acquired a new stake in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 47,794 shares of the company's stock, vApril 14, 2025 | marketbeat.comCenterBook Partners LP Invests $1.36 Million in Soleno Therapeutics, Inc. (NASDAQ:SLNO)CenterBook Partners LP bought a new stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 30,136 shares of the company's stock, valued at approximately $1,3April 13, 2025 | marketbeat.comVanguard Group Inc. Purchases 303,806 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO)Vanguard Group Inc. increased its position in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 19.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,884,533 shares of the company's stock aApril 12, 2025 | marketbeat.comSoleno Therapeutics (NASDAQ:SLNO) Trading Down 9.4% - Here's What HappenedSoleno Therapeutics (NASDAQ:SLNO) Shares Down 9.4% - Here's What HappenedApril 10, 2025 | marketbeat.comKLP Kapitalforvaltning AS Takes Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO)KLP Kapitalforvaltning AS acquired a new stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,300 shares of the company's stock, valuedApril 10, 2025 | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Acquired by Sei Investments Co.Sei Investments Co. increased its position in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 47.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 16,444 shares of the company's stock after acquiring an additionApril 10, 2025 | marketbeat.comSoleno Therapeutics put volume heavy and directionally bearishApril 10, 2025 | markets.businessinsider.comADAR1 Capital Management LLC Increases Stock Holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO)ADAR1 Capital Management LLC boosted its position in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 268.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 36,830 shares of tApril 9, 2025 | marketbeat.comAtika Capital Management LLC Takes Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO)Atika Capital Management LLC acquired a new position in Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 70,700 shares of the company's stock, valued at approximately $3,178,000. AtikaApril 8, 2025 | marketbeat.comWellington Management Group LLP Has $35.16 Million Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO)Wellington Management Group LLP raised its position in Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 14.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 782,265 shares of the company's stock after purchasing an additionalApril 8, 2025 | marketbeat.comCinctive Capital Management LP Invests $594,000 in Soleno Therapeutics, Inc. (NASDAQ:SLNO)Cinctive Capital Management LP bought a new position in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 13,223 shares of the company's stoApril 6, 2025 | marketbeat.comSoleno Therapeutics (NASDAQ:SLNO) Reaches New 1-Year High - Time to Buy?Soleno Therapeutics (NASDAQ:SLNO) Sets New 12-Month High - What's Next?April 5, 2025 | marketbeat.comQ1 EPS Estimate for Soleno Therapeutics Lifted by AnalystSoleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) - Equities researchers at HC Wainwright raised their Q1 2025 earnings per share estimates for Soleno Therapeutics in a note issued to investors on Monday, March 31st. HC Wainwright analyst R. Selvaraju now anticipates that the company will earApril 5, 2025 | marketbeat.comBryce Point Capital LLC Purchases New Stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO)Bryce Point Capital LLC purchased a new stake in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 13,802 shares of the company's stock, valued at aApril 5, 2025 | marketbeat.comPatricia C. Hirano Sells 3,782 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) StockSoleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) insider Patricia C. Hirano sold 3,782 shares of the company's stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $70.11, for a total transaction of $265,156.02. Following the completion of the sale, the insider now directly owns 27,036 shares of the company's stock, valued at $1,895,493.96. The trade was a 12.27 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.April 4, 2025 | marketbeat.comSoleno Therapeutics (NASDAQ:SLNO) Shares Down 6.7% After Insider SellingSoleno Therapeutics (NASDAQ:SLNO) Trading Down 6.7% Following Insider SellingApril 3, 2025 | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Insider Sells $265,156.02 in StockApril 3, 2025 | insidertrades.comWinners and wishers: 8 potential Bay Area drug approvals coming this yearApril 2, 2025 | bizjournals.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Director Matthew Pauls Sells 5,937 SharesSoleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) Director Matthew Pauls sold 5,937 shares of the business's stock in a transaction dated Friday, March 28th. The shares were sold at an average price of $71.55, for a total value of $424,792.35. Following the transaction, the director now owns 6,500 shares in the company, valued at approximately $465,075. This represents a 47.74 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.April 1, 2025 | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) VP Sells $1,013,664.33 in StockSoleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) VP Michael F. Huang sold 14,583 shares of the stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $69.51, for a total transaction of $1,013,664.33. Following the sale, the vice president now owns 36,817 shares in the company, valued at $2,559,149.67. This represents a 28.37 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.April 1, 2025 | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) CFO James H. Mackaness Sells 90,622 SharesSoleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) CFO James H. Mackaness sold 90,622 shares of the business's stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $69.44, for a total transaction of $6,292,791.68. Following the completion of the sale, the chief financial officer now owns 105,176 shares of the company's stock, valued at approximately $7,303,421.44. The trade was a 46.28 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.April 1, 2025 | marketbeat.comInsider Selling: Soleno Therapeutics, Inc. (NASDAQ:SLNO) Insider Sells 128,653 Shares of StockSoleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) insider Patricia C. Hirano sold 128,653 shares of the company's stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $68.32, for a total transaction of $8,789,572.96. Following the transaction, the insider now owns 55,789 shares in the company, valued at $3,811,504.48. The trade was a 69.75 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.April 1, 2025 | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) CEO Bhatnagar Anish Sells 699,095 SharesSoleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) CEO Bhatnagar Anish sold 699,095 shares of the firm's stock in a transaction that occurred on Thursday, March 27th. The shares were sold at an average price of $67.62, for a total value of $47,272,803.90. Following the completion of the sale, the chief executive officer now directly owns 577,076 shares of the company's stock, valued at $39,021,879.12. The trade was a 54.78 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.April 1, 2025 | marketbeat.comSoleno Therapeutics (NASDAQ:SLNO) Sees Unusually-High Trading Volume After Analyst UpgradeSoleno Therapeutics (NASDAQ:SLNO) Sees Strong Trading Volume on Analyst UpgradeApril 1, 2025 | marketbeat.comSoleno Therapeutics price target raised to $100 from $70 at H.C. WainwrightApril 1, 2025 | markets.businessinsider.comSoleno Therapeutics (NASDAQ:SLNO) Price Target Raised to $100.00HC Wainwright raised their price target on Soleno Therapeutics from $70.00 to $100.00 and gave the stock a "buy" rating in a report on Monday.April 1, 2025 | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Purchased by Pictet Asset Management Holding SAPictet Asset Management Holding SA raised its stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 48.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 851,838 shares of the company's stock after buyiApril 1, 2025 | marketbeat.comInsider Selling: Soleno Therapeutics, Inc. (NASDAQ:SLNO) Director Sells $424,792.35 in StockApril 1, 2025 | insidertrades.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Receives Average Rating of "Buy" from AnalystsShares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) have been assigned an average rating of "Buy" from the nine research firms that are presently covering the stock, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation and two hMarch 31, 2025 | marketbeat.comFY2025 EPS Estimates for SLNO Reduced by Cantor FitzgeraldSoleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) - Equities researchers at Cantor Fitzgerald decreased their FY2025 earnings estimates for shares of Soleno Therapeutics in a research report issued to clients and investors on Thursday, March 27th. Cantor Fitzgerald analyst K. Kluska now anticMarch 31, 2025 | marketbeat.comWhat is Lifesci Capital's Forecast for SLNO Q1 Earnings?Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) - Equities research analysts at Lifesci Capital lowered their Q1 2025 earnings per share estimates for Soleno Therapeutics in a report released on Thursday, March 27th. Lifesci Capital analyst M. Belghiti now anticipates that the company willMarch 31, 2025 | marketbeat.comWhy Soleno Therapeutics Inc. (SLNO) Went Up Last Week?March 30, 2025 | msn.comSoleno Therapeutics (NASDAQ:SLNO) Given New $108.00 Price Target at Stifel NicolausStifel Nicolaus upped their target price on shares of Soleno Therapeutics from $74.00 to $108.00 and gave the stock a "buy" rating in a research note on Friday.March 29, 2025 | marketbeat.comSoleno Therapeutics (NASDAQ:SLNO) Shares Up 3.9% on Analyst UpgradeSoleno Therapeutics (NASDAQ:SLNO) Shares Up 3.9% on Analyst UpgradeMarch 29, 2025 | marketbeat.com Get Soleno Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter. Email Address SLNO Media Mentions By Week SLNO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SLNO News Sentiment▼1.520.74▲Average Medical News Sentiment SLNO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SLNO Articles This Week▼105▲SLNO Articles Average Week Get Soleno Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Smith & Nephew News Solventum News Penumbra News Stevanato Group News Glaukos News Inari Medical News Inspire Medical Systems News Bausch + Lomb News iRhythm Technologies News TransMedics Group News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SLNO) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soleno Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soleno Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SLNO Stock Free SLNO Stock Alerts